Giapreza is owned by La Jolla Pharma.

Giapreza contains Angiotensin Ii Acetate.

Giapreza has a total of 11 drug patents out of which 0 drug patents have expired.

Giapreza was authorised for market use on 21 December, 2017.

Giapreza is available in solution;intravenous dosage forms.

Giapreza can be used as maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use, treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor, treating distributive shock with angiotensin ii; treating septic shock with angiotensin ii, treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension, and titrating the rate up; treating low blood pressure with angiotensin ii with an initial rate of about 5 ng/kg/min to about 20 ng/kg/min in a subject having refractory hypotension or severe hypotension, increasing blood pressure with a rate of about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock; increasing blood pressure with an initial rate of about 20 ng/kg/min angiotensin ii in a human subject having septic shock, and titrating the rate up., maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and reducing catecholamine use; treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use, increasing blood pressure in a patient having distributive shock, treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor, treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angiotensin ii in a human subject having septic shock, treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above, treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor.

Drug patent challenges can be filed against Giapreza from 2021-12-21.

The generics of Giapreza are possible to be released after 06 January, 2037.